Clinical Trials Logo

Clinical Trial Summary

Primary Sclerosing Cholangitis (PSC) is a progressive liver disorder of unknown cause. Current evidence suggests that genes, the genetic material we inherit from our parents, in combination with environmental factors, likely play an important role in the development of PSC. This study is being done to investigate whether genes make people more likely to develop PSC. Discovery of these genes will help us to better understand how PSC developes and subsequently, to apply new approaches for its prevention, diagnosis and treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01161992
Study type Observational
Source Mayo Clinic
Contact
Status Active, not recruiting
Phase
Start date March 2002
Completion date December 2050

See also
  Status Clinical Trial Phase
Completed NCT05082779 - Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CS0159 Phase 1
Completed NCT06037577 - Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects Phase 1
Completed NCT01672853 - Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Adults With Primary Sclerosing Cholangitis (PSC) Phase 2
Completed NCT02061540 - Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis Phase 2
Completed NCT01819766 - Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease N/A
Completed NCT02808312 - Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function Phase 1
Completed NCT03333928 - A POC and Dose-Ranging Study of HTD1801 in PSC Patients Phase 2
Completed NCT02177136 - Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC) Phase 2
Completed NCT03766035 - Cholangioscopy in Primary Sclerosing Cholangitis (PSC)
Completed NCT01695174 - A Pilot Study of Xifaxan to Treat Patients With PSC Phase 1
Recruiting NCT06026865 - S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC) N/A